Emcure Pharmaceuticals Limited – Investor Presentation Summary
Key Operational Highlights
- USD 1Bn+ Operating Revenue FY26
- Revenue growth of +16.6% in FY26
- PAT Growth of 33.1% in FY26 with 120 bps YoY margin expansion
- 80+ countries operational presence
- 900+ products launched across markets
- 4,000+ MR strength field force with pan-Indian presence
- 19/20 top brands (> INR 500 Mn) ranked top 3 in their category
- ~30% revenue share from complex products
Key drivers of operational performance: Chronic mix expansion, deeper women's health franchise, complex product capabilities, and international front-end expansion.
Segment-wise Performance
- Domestic Revenue: ₹40,270 Mn (+10.0% YoY) with 60%+ chronic mix
- International Revenue: ₹51,766 Mn (+22.2% YoY) representing 56% of group revenue
- Europe: ₹18,498 Mn (+25.5% YoY) - complex injectables and specialty generics
- Canada: ₹14,869 Mn (+18.7% YoY) - pan-Canada front end + first-generics
- Rest of World: ₹18,399 Mn (+21.8% YoY) - non-ARV/biosimilars/complex generics + ARV scale
Explanation of significant changes in segment performance: International growth driven by differentiated portfolio expansion across all regions, while domestic growth supported by chronic therapy penetration and brand leadership.
Financial Highlights
Revenue: ₹92,035 Mn
EBITDA: ₹17,886 Mn
PAT: ₹9,413 Mn
EPS: ₹48.7
Margins: Gross Profit Margin 60.3% (+20 bps YoY), EBITDA Margin 19.4% (+80 bps YoY), PAT Margin 10.2% (+120 bps YoY)
YoY/QoQ comparison: Q1 FY27 revenue ₹25,804 Mn (+22.8% YoY, +4.5% QoQ), PAT ₹2,925 Mn (+36.2% YoY, +20.0% QoQ)
Drivers of financial performance: Higher revenue growth, operational efficiencies, complex product mix improvement
Comparison to market estimates: Not Specified
Key Risks: Regulatory changes, competitive pressures, technology changes, supply chain challenges, currency fluctuations
Geographical Revenue Split
Domestic vs Export/Regional Revenue:
Domestic: ₹40,270 Mn, 44% of Total
International: ₹51,766 Mn, 56% of Total
Regional Breakdown: Europe (20% of total revenue), Canada (16% of total revenue), Rest of World (20% of total revenue)
Balance Sheet Snapshot
Net Debt/Equity: Not Specified
Reserves: ₹47,604 Mn
Current Assets/Liabilities: Current Assets ₹56,121 Mn, Current Liabilities Not Specified
Working Capital/Leverage Metrics: Net working capital increase of ₹5,301 Mn in FY26
Financial Health Insights: Strong revenue growth, margin expansion, and increased shareholder funds to ₹49,500 Mn
Capex & Cash Flow Health
Capital Expenditure: ₹3,606 Mn on PP&E, CWIP and leasehold in FY26
Free Cash Flow: Not Specified
Operating Cash Flow: ₹9,435 Mn in FY26
Net Debt Movement: Borrowings increased to ₹12,041 Mn from ₹7,317 Mn
Investment Rationale: Focus on complex injectables, oncology and novel delivery platforms industrialization
Strategic & R&D Initiatives
Investments in Innovation: Biologics, Novel Drug Delivery System (NDDS), Complex Injectables, Long-Acting Injectables (LAI), Antibody-Drug Conjugates (ADC)
Expected impact on growth: Pipeline assets concentrated in metabolics (Semaglutide ex-India), ophthalmology (Bevacizumab), oncology, anti-infectives, HIV Anti-Viral (Lenacapavir), dermatology, respiratory, gynaecology (Ferric Carboxymaltose Global)
Strategic Rationale: Expanding into high-growth therapeutic areas, reducing operational costs through API-to-formulation integration
Industry Trends & Business Environment
Macro/Industry Trends: 50%+ of women and 25% of men are anaemic in India; 3 in 4 Indian women have low dietary iron intake; dermatology industry growing at ~12-15%
Impact on Company: Market shaping through 14,000 anaemia-detection camps reaching over 200,000 women; expanding women's health continuum across infertility, PCOS and obesity management
Management Commentary & Growth Outlook
Strategic Outlook: Three strategic priorities underpin FY26-FY30 growth aspiration: deepen domestic franchise, scale differentiated international portfolios, translate differentiated R&D platforms into commercial launches
FY Guidance: Not Specified
Market Share Targets: #2 rank in Gynaecology with 8.3% share, #13 largest player, #9 rank by market share in covered market
Risks and Opportunities: Regulatory changes, competitive pressures, technology changes, supply chain challenges, currency fluctuations, ability to obtain or maintain approvals, product commercialisation timelines